BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Adzynma (Apadamtase alfa) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Adzynma (Apadamtase alfa)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04683003-10318@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Adzynma (Apadamtase alfa): Phase 3 readout est. (NCT04683003)
DESCRIPTION:Adzynma (Apadamtase alfa)\, phase 3.\nStudy: A Study of TAK-755
  in Participants With Congenital Thrombotic Thrombocytopenic Purpura\nEsti
 mated primary completion: 16 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/apadamtase-alfa#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04683003
URL:https://assetmemo.bio/drug/apadamtase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392450-10318@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Adzynma (Apadamtase alfa): Phase 2 readout est. (NCT07392450)
DESCRIPTION:Adzynma (Apadamtase alfa)\, phase 2\, Acute Ischemic Stroke.\nS
 tudy: A Study of TAK-755 in Adults With Acute Ischemic Stroke\nEstimated p
 rimary completion: 6 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/apadamtase-alfa#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07392450
URL:https://assetmemo.bio/drug/apadamtase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
